Shenzhen Bioeasy Biotechnology Co., Ltd.

XSEC:300942 Stock Report

Market Cap: CN¥4.3b

Shenzhen Bioeasy Biotechnology Past Earnings Performance

Past criteria checks 0/6

Shenzhen Bioeasy Biotechnology's earnings have been declining at an average annual rate of -48.3%, while the Medical Equipment industry saw earnings growing at 6.1% annually. Revenues have been declining at an average rate of 1.5% per year.

Key information

-48.3%

Earnings growth rate

-48.8%

EPS growth rate

Medical Equipment Industry Growth16.0%
Revenue growth rate-1.5%
Return on equity-9.7%
Net Margin-33.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Shenzhen Bioeasy Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

XSEC:300942 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24247-8211333
30 Jun 24246-11712233
31 Mar 24230-16414845
31 Dec 23254-18515553
30 Sep 23280-16513199
30 Jun 23324-138144111
31 Mar 23454-59136114
01 Jan 2368783155111
30 Sep 2273918917687
30 Jun 2274222514684
31 Mar 2274526312877
01 Jan 2259823710272
30 Sep 215032098654
30 Jun 214571908550
31 Mar 213331188541
31 Dec 20258657539
30 Sep 202829011862
31 Mar 202691146035
31 Dec 19239926132
31 Dec 18205744723
31 Dec 17138394522
31 Dec 1687233116

Quality Earnings: 300942 is currently unprofitable.

Growing Profit Margin: 300942 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 300942 is unprofitable, and losses have increased over the past 5 years at a rate of 48.3% per year.

Accelerating Growth: Unable to compare 300942's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 300942 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-8.8%).


Return on Equity

High ROE: 300942 has a negative Return on Equity (-9.7%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies